Your browser doesn't support javascript.
loading
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers.
Felip, Enriqueta; Moreno, Victor; Morgensztern, Daniel; Curigliano, Giuseppe; Rutkowski, Piotr; Trigo, José Manuel; Calvo, Aitana; Kowalski, Dariusz; Cortinovis, Diego; Plummer, Ruth; Maio, Michele; Ascierto, Paolo A; Vladimirov, Vladimir I; Cervantes, Andres; Zudaire, Enrique; Hazra, Anasuya; T'jollyn, Huybrecht; Bandyopadhyay, Nibedita; Greger, James G; Attiyeh, Edward; Xie, Hong; Calvo, Emiliano.
Afiliação
  • Felip E; Thoracic Cancer Unit, Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Moreno V; Phase 1 Trials Unit, START MADRID-FJD, Hospital Fundación Jiménez Díaz Medical Oncology Division, Madrid, Spain.
  • Morgensztern D; Division of Oncology, Section of Medical Oncology, Washington University School of Medicine, St. Louis, MO, USA.
  • Curigliano G; Division of Early Drug Development, European Institute of Oncology, IRCCS and University of Milano, Milan, Italy.
  • Rutkowski P; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Trigo JM; Department of Medical Oncology, Hospital Universitario Virgen de La Victoria y Regional, Malaga, Spain.
  • Calvo A; Oncology Service, Hospital General Universitario Gregorio Maranon, Madrid, Spain.
  • Kowalski D; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Cortinovis D; Oncology Unit, San Gerardo Hospital, Monza, Italy.
  • Plummer R; Sir Bobby Robson Unit, Northern Centre for Cancer Care, Newcastle Hospitals NHS Trust and Newcastle University, Newcastle, UK.
  • Maio M; Center for Immuno-Oncology, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy.
  • Ascierto PA; Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS-Fondazione Pascale, Napoli, Italy.
  • Vladimirov VI; Pyatigorsky Oncology Dispensary, Pyatigorsk, Russia.
  • Cervantes A; Medical Oncology Department, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Zudaire E; Janssen Research & Development, Spring House, PA, USA.
  • Hazra A; Janssen Research & Development, Spring House, PA, USA.
  • T'jollyn H; Janssen Research & Development, Beerse, Belgium.
  • Bandyopadhyay N; Janssen Research & Development, Raritan, NJ, USA.
  • Greger JG; Janssen Research & Development, Spring House, PA, USA.
  • Attiyeh E; Janssen Research & Development, Spring House, PA, USA.
  • Xie H; Janssen Research & Development, Spring House, PA, USA.
  • Calvo E; Centro Integral Oncológico Clara Campal Medical Oncology Division, START Madrid-CIOCC, Sanchinarro University Hospital, Madrid, Spain. emiliano.calvo@startmadrid.com.
Cancer Chemother Pharmacol ; 89(4): 499-514, 2022 04.
Article em En | MEDLINE | ID: mdl-35298698
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares / Melanoma / Neoplasias Limite: Humans Idioma: En Revista: Cancer Chemother Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares / Melanoma / Neoplasias Limite: Humans Idioma: En Revista: Cancer Chemother Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha